FDA Brief

Warning letters Drugs

FDA warning letter to

FirstCham Co., Ltd.

High riskIssued Apr 3, 2024Posted Apr 9, 2024Center for Drug Evaluation and Research | CDER

FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

What happened

FDA inspected FirstCham's drug manufacturing facility from October 23 to 27, 2023. FDA found CGMP violations in raw material identity testing, including glycerin; laboratory records; process validation; the water system; and quality control oversight. FDA also reviewed the Soo'Ae Hand Sanitizing Wipes website and found 'FDA registered' and an FDA-like logo that misleadingly suggested FDA approval or endorsement.

What FDA found

  1. FirstCham did not test each incoming lot of raw materials for identity, including glycerin, and relied on supplier certificates without proving the suppliers' test results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. Its laboratory records did not include complete data, such as test methods, results, equipment used, and confirmation of testing conditions.

    21 CFR 211.194(a)
  3. It did not validate its manufacturing processes to show they consistently make uniform, quality drug products.

    21 CFR 211.100(a) and 211.100(b)
  4. Its water system had multiple dead-legs and a non-circulating loop and was not adequately monitored for microbial limits.

    21 CFR 211.100(a) and 211.100(b)
  5. Its quality control unit did not provide adequate oversight and did not establish written procedures for validation, qualification, supplier qualification, and other quality tasks.

    21 CFR 211.22
  6. The Soo'Ae Hand Sanitizing Wipes website said 'FDA registered' and used an FDA-like logo, misleadingly suggesting FDA approval or endorsement.

    section 502(a) of the FD&C Act, 21 U.S.C. 352(a)

What FDA wants

FDA asks FirstCham to provide DEG and EG test results from retained component lots or implicated finished batches within 30 calendar days, and to submit a risk assessment and detailed corrective action plans for U.S. products within expiry. FDA also recommends a qualified CGMP consultant perform a six-system audit.

Who should pay attention

  • brands and distributors selling FirstCham OTC hand sanitizer products in the U.S.
  • companies buying glycerin-containing wipes or sanitizers from this manufacturer
  • U.S. retailers and consumers using Soo'Ae hand sanitizing wipes

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk